Guy Chamberland

Bioscience firm that's developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers.